Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Shareholders of NovaBev approved dividends

12/18/23 BELU

UTair passenger traffic on airplanes in January-November increased by 9.4%

12/18/23 UTAR

MTS will develop a new format of retail stores

12/18/23 MTSS

MS-21 made the first time automatic landing under category IIIA

12/15/23 UNAC

Etalon Group shareholders approved the redomiciliation

12/15/23 ETLN

Shareholders of Phosagro approved dividends

12/15/23 PHOR

Sovcombank's IPO is attended by 140 thousand investors

12/15/23 SVCB

Segezha Group increases production of Segezha Vulcan plywood

12/15/23 SGZH

Fix Price scales technology to recognize queues at the cash register

12/15/23 FIXP

MTS Bank wants to create an MFO

12/15/23 MTSS